There are 2949 resources available
1279P - Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)
Presenter: Julien Mazieres
Session: E-Poster Display
Resources:
Abstract
1280P - Analysis of ARID1A and ARID1B as potential biomarkers for NSCLC immunotherapy
Presenter: Chongbiao Huang
Session: E-Poster Display
Resources:
Abstract
1281P - The prognostic impact of tissue tumour mutational burden (TMB) in the first-line treatment of advanced non-oncogene addicted non-small cell lung cancer (NSCLC): A systematic review and meta-analysis of randomized controlled trials
Presenter: Valerio Gristina
Session: E-Poster Display
Resources:
Abstract
1282P - Trial-based costs of all-cause adverse events in first-line therapy for advanced non-small cell lung cancer: Findings from CheckMate-227
Presenter: Solomon J Lubinga
Session: E-Poster Display
Resources:
Abstract
1283P - Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A
Presenter: Julien Mazieres
Session: E-Poster Display
Resources:
Abstract
1284P - MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
Presenter: Enriqueta Felip
Session: E-Poster Display
Resources:
Abstract
1285P - Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study
Presenter: Johan Vansteenkiste
Session: E-Poster Display
Resources:
Abstract
1286P - Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC
Presenter: Santiago Viteri
Session: E-Poster Display
Resources:
Abstract
1287P - Efficacy and safety of entrectinib in locally advanced/metastatic <italic>ROS1</italic> fusion-positive NSCLC: An updated integrated analysis
Presenter: Matthew G Krebs
Session: E-Poster Display
Resources:
Abstract
1288P - Efficacy of entrectinib in patients with <italic>NTRK</italic> or <italic>ROS1</italic> fusion-positive NSCLC with CNS metastases at baseline
Presenter: Rafal Dziadziuszko
Session: E-Poster Display
Resources:
Abstract